ID1 and plasma cell myeloma: However, since there was no difference in myeloma development between normal and SH2D2A-deficient BALB/c mice, the enhanced tumor protection observed in the SH2D2A-deficient Id-specific TCR-transgenic mice is difficult to ascribe to endothelial cells and angiogenesis alone.